BYON4228

· Byondis B.V.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BYON4228, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 [Phase 1]